SNPMiner Trials (Home Page)
Report for Mutation D594G
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.
NCT01922583 Non-small Cell Lung Cancer (NSCLC) Drug: AUY922 MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma
G469A, D594G). --- G469A --- --- D594G ---
Primary Outcomes
Description: To define the by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC
Measure: Objective response rate Time: Patients will be followed up for 2 years(post disease progression)Secondary Outcomes
Description: Patients will be followed for progression-free survival (PFS) and overall survival (OS) which will be analyzed by using a Kaplan-Meier curve. Patients will be followed up for PFS and OS for 2 years.
Measure: Efficacy, progression-free survival (PFS) Time: Patients will be followed up for PFS and OS for 2 years.(post disease progression)Description: Patients will be followed for overall survival (OS)
Measure: overall survival (OS) Time: Patients will be followed up for OS for 2 years.(post disease progression)